prikaz prve stranice dokumenta Učinkovitost i sigurnost ibrutiniba u liječenju kronične limfocitne leukemije : iskustvo Zavoda za hematologiju KBC-a Split
  Download
PDF 1.03 MB
master's thesis
Učinkovitost i sigurnost ibrutiniba u liječenju kronične limfocitne leukemije : iskustvo Zavoda za hematologiju KBC-a Split
2022. urn:nbn:hr:171:359615
Matas, Nina
University of Split
School of Medicine

Cite this document

Matas, N. (2022). Učinkovitost i sigurnost ibrutiniba u liječenju kronične limfocitne leukemije : iskustvo Zavoda za hematologiju KBC-a Split (Master's thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:359615

Matas, Nina. "Učinkovitost i sigurnost ibrutiniba u liječenju kronične limfocitne leukemije : iskustvo Zavoda za hematologiju KBC-a Split." Master's thesis, University of Split, School of Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:171:359615

Matas, Nina. "Učinkovitost i sigurnost ibrutiniba u liječenju kronične limfocitne leukemije : iskustvo Zavoda za hematologiju KBC-a Split." Master's thesis, University of Split, School of Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:171:359615

Matas, N. (2022). 'Učinkovitost i sigurnost ibrutiniba u liječenju kronične limfocitne leukemije : iskustvo Zavoda za hematologiju KBC-a Split', Master's thesis, University of Split, School of Medicine, accessed 28 November 2024, https://urn.nsk.hr/urn:nbn:hr:171:359615

Matas N. Učinkovitost i sigurnost ibrutiniba u liječenju kronične limfocitne leukemije : iskustvo Zavoda za hematologiju KBC-a Split [Master's thesis]. Split: University of Split, School of Medicine; 2022 [cited 2024 November 28] Available at: https://urn.nsk.hr/urn:nbn:hr:171:359615

N. Matas, "Učinkovitost i sigurnost ibrutiniba u liječenju kronične limfocitne leukemije : iskustvo Zavoda za hematologiju KBC-a Split", Master's thesis, University of Split, School of Medicine, Split, 2022. Available at: https://urn.nsk.hr/urn:nbn:hr:171:359615

Please login to the repository to save this object to your list.
Metadata
TitleUčinkovitost i sigurnost ibrutiniba u liječenju kronične limfocitne leukemije : iskustvo Zavoda za hematologiju KBC-a Split
Title (english)Efficacy and safety of ibrutinib in the treatment of chronic lymphocytic leukemia : experience of the Department of Hematology University Hospital of Split
AuthorNina Matas
MentorDavor Galušić (mentor)
Committee memberMaja Radman (predsjednik povjerenstva)
Committee memberDaniela Marasović Krstulović (član povjerenstva)
Committee memberIvana Pavlinac Dodig (član povjerenstva)
GranterUniversity of Split
School of Medicine
Split
Defense date and country2022, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract
Cilj istraživanja: Cilj ovog istraživanja bio je ispitati učinkovitost i sigurnost ibrutiniba u liječenju kronične limfocitne leukemije u stvarnoj kliničkoj praksi. Ispitanici i metode: Prikupljeni su medicinski podaci 57 ispitanika koji su liječenje ibrutinibom započeli u Zavodu za hematologiju KBC Split u periodu od lipnja 2015. do lipnja 2021. Ovo opservacijsko istraživanje temelji se na retrospektivnom pregledu i analizi medicinske dokumentacije bolesnika s dijagnozom kronične limfocitne leukemije kojima je uveden ibrutinib neovisno radi li se o novodijagnosticiranoj ili relapsno-refraktornoj bolesti. Rezultati: Većinu našeg uzorka čine ispitanici nepovoljnije prognoze (Rai 3-4 u 72%). Ukupni odgovor na terapiju bio je 91% (KR 82%, PR 9%). Medijan praćenja bolesnika iznosio je 16,3 mjeseca. Nakon 24 mjeseca stopa ukupnog preživljenje (OS) iznosila je 88,45%, a preživljenja bez progresija (TTP) 96,16%. Medijan OS, kao ni medijan TTP, nije dostignut. Utvrđena je statistički značajno viša stopa ukupnog preživljenje (OS) bolesnika mlađih od 60 godina u odnosu na bolesnike starije od 60 godina (100% vs. 86% nakon 24 mjeseca, P = 0,04). Kompletna remisija (KR) kao odgovor na terapiju i liječenje ibrutinibom u prvoj liniji statistički značajno koreliraju s duljim TTP ispitanika (P = 0,001 i P = 0,05). Nuspojave su većinom bile blage prirode dok su one gradusa 3 i 4 bile rijetke (10% bolesnika). Zaključci: Ibrutinib je iznimno učinkovit i siguran lijek u svakodnevnoj kliničkoj praksi. Nužan je dulji period praćenje ishoda i nuspojava u svrhu usporedbe s drugim istraživanjima, ali i zbog predviđanja dugoročne prognoze ovih bolesnika.
Abstract (english)
Objectives: The aim of this research was to examine the effectiveness and safety of ibrutinib in the treatment of chronic lymphocytic leukemia in real clinical practice. Subjects and methods: The medical data of 57 subjects who started treatment with ibrutinib at the Department of Hematology of KBC Split in the period from June 2015 to June 2021 were collected. This observational research is based on a retrospective review and analysis of hospital data of patients with a diagnosis of chronic lymphocytic leukemia who were introduced to ibrutinib, regardless of whether it is a newly diagnosed or relapsing-refractory disease. Results: The majority of our sample consists of subjects with a less favorable prognosis (Rai 3-4 in 72%). The overall response to therapy was 91% (KR 82%, PR 9%). Median follow-up was 16.3 months. 24 months overall survival (OS) rate was 92% and 24 months progression-free survival (TTP) rate was 96%. The OS rate of elderly patients (>60 years) is statistically significantly lower than younger patients (86% vs. 100% after 24 months, P = 0.04). Complete remission (CR) as a response to therapy and first line ibrutinib treatment are associated with longer TTP (P = 0.001 and P = 0.05). Side effects were mostly mild, while grade 3 and 4 toxicity were rare (10% of patients). Conclusions: Ibrutinib is considered safe and effective in daily clinical practice. A longer period of monitoring of the outcomes and side effects of this research is necessary for the purpose of comparison with other studies and for predicting the long-term prognosis of these patients.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:171:359615
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-09-05 08:54:20